Research Article| Volume 142, ISSUE 1, P105-112, January 03, 1999

Download started.


Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management


      Clinical management of heterozygous familial hypercholesterolaemia is largely based on evidence from a small number of observational studies and extrapolation from the results of clinical trials of lipid-lowering in patients with polygenic hypercholesterolaemia The objectives of this study were (i) to determine the absolute and relative mortality of patients with treated heterozygous familial hypercholesterolaemia, (ii) to estimate the effect of changes in treatment efficacy on mortality trends over time, and (iii) to examine the implications of these findings for patient management. A cohort of 605 men and 580 women aged 20–79 years with heterozyous familial hypercholesterolaemia were recruited from 21 out-patient lipid clinics in the UK. Patients were followed prospectively from 1980 to 1995 for 8770 person-years. Absolute mortality was calculated, and relative risk was expressed as the ratio of the number of observed deaths to the number expected in the general population of England and Wales. Forty six of the 73 deaths were due to coronary heart disease. In women aged 20–39, despite treatment, the relative risk of a fatal coronary event was increased 125-fold (95% confidence intervals 15–451) and the annual coronary mortality was 0.17%. In men aged 20–39 the relative risk was increased 48-fold (17-105) and the annual coronary mortality was 0.46%. The relative risk decreased with age but the absolute risk increased. For men and women aged 60–79, the annual coronary mortality was 1.1% representing a significant excess mortality for women (relative risk 2.6, 1.3–4.5) but not for men (RR 1.1, 0.5–2.3). Non-coronary mortality was not increased at any age (RR for all ages 0.68, 0.45–0.99). There was a decline in the relative risk for coronary mortality in patients aged 20–59 from an eight-fold (4.8–7.2) increased risk before 1992 to 3.7 (1.6–7.2.) thereafter (P=0.08). The results suggest that the prognosis for patients with heterozygous familial hypercholesterolaemia has improved with the introduction of more effective treatment, and that lipid-lowering therapy is not associated with increased non-coronary mortality. These findings and the excess coronary mortality observed suggest that all affected adult men and post-menopausal women should be treated with HMG-CoA reductase inhibitors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Goldstein J.L.
        • Brown M.S.
        Familial hypercholesterolaemia.
        in: Stanbury J.B. Wyngaarden J.B. Fredrickson D.S. Goldstein J.L. Brown M.S. The metabolic basis of inherited disease. 5th edn. McGraw-Hill, New York1983: 672-712
      1. Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. B Med J 1991;303:893–6.

      2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.
        • Lorimer A.R.
        • MacFarlane P.W.
        • et al.
        Prevention of coronary heart disease in men with hypercholesterolaemia.
        New Engl J Med. 1995; 333: 1301-1307
        • Newman T.B.
        • Hulley S.B.
        Carcinogenicity of lipid-lowering drugs.
        J Am Med Assoc. 1996; 275: 55-60
        • Jackson R.
        Evidence-based management of dyslipidaemia.
        Lancet. 1995; 346: 1440-1441
        • Ramsey L.E.
        • Haq I.U.
        • Jackson P.R.
        • Yeo W.W.
        The Sheffield table for primary prevention of coronary disease: corrected.
        Lancet. 1996; 348: 1251-1252
        • Anderson K.M.
        • Odell P.M.
        • Wilson P.W.F.
        • Kannel W.B.
        Cardiovascular disease risk profiles.
        Am Heart J. 1990; 121: 293-298
        • Friedewald W.T.
        • Levy R.I.
        • Fredickson D.S.
        Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Coleman M.
        • Douglas A.
        • Hermon C.
        • Peto J.
        Cohort study analysis with a Fortran computer program.
        Int J Epidemiol. 1986; 15: 134-137
        • Breslow N.E.
        • Day N.E.
        The design and analysis of cohort studies.
        in: Statistical analysis in cancer research. 2. Oxford University Press, Oxford1988: 69
        • Jensen J.
        • Blackenhorn D.H.
        • Kornerup V.
        Coronary disease in familial hypercholesterolaemia.
        Circulation. 1976; 36: 77-82
        • Manolio T.A.
        • Pearson T.A.
        • Wenger N.K.
        • Barrett-Connor E.
        • Payne G.H.
        • Harlan W.R.
        Cholesterol and heart disease in older persons and women: review of an NHLBI workshop.
        Ann Epidemiol. 1992; 2: 155-160
        • Stamler J.
        • Wentworth D.
        • Neaton S.D.
        Is relationship between cholesterol and risk of premature death from coronary heart disease continuous and graded?.
        J Am Med Assoc. 1986; 256: 2823-2828
        • Heiberg A.
        • Slack J.
        Family similarities in the age at coronary death in familial hypercholesterolaemia.
        B Med J. 1977; 2: 493-495
        • Vohl M.C.
        • Gaudet D.
        • Moorjani S.
        • Tremblay G.
        • Perron P.
        • Gagne C.
        • et al.
        Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia.
        Eur J Clin Invest. 1997; 27: 366-373
        • Jeenah M.
        • September W.
        • van Roggen F.G.
        • de Villiers W.
        • Seftel H.
        • Marais D.
        Influence of specific mutations at the LDL receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
        Atherosclerosis. 1993; 98: 51-58
        • Thompson G.R.
        • Seed M.
        • Niththyananthan S.
        • McCarthy S.
        • Thorogood M.
        Genotypic and phenotypic variation in familial hypercholesterolaemia.
        Atherosclerosis. 1989; 9: 75-80
        • Eto M.
        • Watanabe M.
        • Chonan H.
        • Ishii K.
        Familial hypercholesterolaemia and apolipoprotein E4.
        Atherosclerosis. 1988; 72: 123-128
        • Seed M.
        • Hoppichler F.
        • Reaveley D.
        • McCarthy S.
        • Thompson G.R.
        • Boerwinkle E.
        • et al.
        Relation of serum lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia.
        New Engl J Med. 1990; 322: 1494-1499
        • Miettinen T.A.
        • Gylling H.
        Mortality and cholesterol metabolism in familial hypercholesterolaemia.
        Atherosclerosis. 1988; 8: 163-167
        • Hill J.S.
        • Hayden M.R.
        • Frohlich J.
        • Pritchard P.H.
        Genetic and environmental factors affecting the incidence of coronary heart disease in heterozygous familial hypercholesterolaemia.
        Atheroscler Thromb. 1991; 11: 290-297
        • Beaumont V.B.
        • Jacotot B.
        • Beaumont J.-L.
        Ischaemic disease in men and women with familial hpercholesterolaemia and xanthomatosis.
        Atherosclerosis. 1976; 24: 441-450
        • Streja D.
        • Steiner G.
        • Kwiterovich P.O.
        Plasma high-density lipoproteins and ischemic heart disease.
        Ann Intern Med. 1978; 89: 871-880
        • Moorjani S.
        • Gagne C.
        • Lupien P.J.
        • Brun D.
        Plasma triglyceride-related disease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolaemia.
        Metabolism. 1986; 35: 311-316
      3. Colhoun H, Prescott-Clarke P, editors. Health Survey for England 1994, Vol. 1: Findings. London: HMSO, 1996.

        • Sacks F.M.
        • Peffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        New Engl Med J. 1996; 335: 1001-1009
      4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:365–74.

        • Durrington P.N.
        Normal lipid and lipoprotein levels in childhood and adolescence.
        in: Neil A. Rees A. Taylor C. Hyperlipidaemia in childhood. Royal College of Physicians of London, London1996: 9-16
        • Volmink J.A.
        • Newton J.
        • Hicks N.
        • Sleight P.
        • Fowler G.H.
        • Neil H.A.W.
        Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infaction Incidence Study.
        Heart. 1998; 79: 40-44
        • Slack J.
        Risks of ischaemic heart disease in familial hyperlipidaemic states.
        Lancet. 1969; ii: 1380-1382
        • Stone N.J.
        • Levy R.I.
        • Fredrickson D.S.
        • Verter J.
        Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia.
        Circulation. 1974; 49: 476-488
        • Durrington P.N.
        Familial hypercholesterolaemia, Ch. 5.
        in: Hyperlipidaemia, diagnosis and management. 2nd edition. Butterworth Heinemann, London1995: 108-139